{"id":947213,"date":"2026-03-27T07:15:32","date_gmt":"2026-03-27T11:15:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/"},"modified":"2026-03-27T07:15:32","modified_gmt":"2026-03-27T11:15:32","slug":"editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/","title":{"rendered":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board\u2019s (PTAB\u2019s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR\/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).<\/p>\n

The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC\u2019s May 2025 decision to affirm-in-part and vacate-in-part the PTAB\u2019s prior decision. This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR\/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision to the CAFC.<\/p>\n

\u201cWe are pleased with decision reaffirming Broad\u2019s inventorship priority for CRISPR\/Cas9 gene editing,\u201d said Gilmore O\u2019Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. \u201cThis outcome reinforces our confidence in our intellectual property as we continue to leverage the power of\u00a0in vivo<\/em> gene editing\u00a0to create transformative medicines for people living with serious diseases. This includes\u00a0the development of EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved an unprecedented greater than 90 percent mean LDL cholesterol reduction in non-human primates.\u201d<\/p>\n

The CRISPR\/Cas9 patents at issue are exclusively licensed to Editas Medicine for the development and commercialization of CRISPR\/Cas9-based medicines.<\/p>\n

Other in-licensed patents from the Broad Institute, Harvard University, MIT, and other institutions covering CRISPR\/Cas9, as well as those in-licensed patents from the Broad Institute and collaborators covering CRISPR\/Cas12a, are not at issue in the interference and are unaffected by this decision.<\/p>\n

Editas Medicine\u2019s foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR\/Cas12a and CRISPR\/Cas9 gene editing in all human cells. Additionally, the Company holds a wide range of fundamental intellectual property directed to all the components of its gene editing platform including product-enabling and product-specific intellectual property covering the use of CRISPR\/Cas12a and CRISPR\/Cas9 for gene editing of human cells in the United States, Australia, Europe, Japan, China, and other jurisdictions.\u00a0<\/p>\n

\n About <\/strong>
\n Editas Medicine<\/strong>
\n
As a pioneering gene editing company,\u00a0Editas Medicine\u00a0is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of\u00a0in vivo\u00a0<\/em>medicines for people living with serious diseases around the world.\u00a0Editas Medicine\u00a0aims to discover, develop, manufacture, and commercialize transformative, durable, precision\u00a0in vivo\u00a0<\/em>gene editing medicines for a broad class of diseases.\u00a0Editas Medicine\u00a0is the exclusive licensee of Broad Institute\u2019s Cas12a patent estate and\u00a0Broad Institute\u00a0and Harvard University\u2019s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit\u00a0www.editasmedicine.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words \u2018\u2018anticipate,\u2019\u2019 \u2018\u2018believe,\u2019\u2019 \u2018\u2018continue,\u2019\u2019 \u2018\u2018could,\u2019\u2019 \u2018\u2018estimate,\u2019\u2019 \u2018\u2018expect,\u2019\u2019 \u2018\u2018intend,\u2019\u2019 \u2018\u2018may,\u2019\u2019 \u2018\u2018plan,\u2019\u2019 \u2018\u2018potential,\u2019\u2019 \u2018\u2018predict,\u2019\u2019 \u2018\u2018project,\u2019\u2019 \u2018\u2018target,\u2019\u2019 \u2018\u2018should,\u2019\u2019 \u2018\u2018would,\u2019\u2019 and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent with litigation, including patent interference proceedings; and uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials. These and other risks are described in greater detail under the caption \u201cRisk Factors\u201d included in the Company\u2019s most recent Annual Report on Form 10-K, which is on file with the\u00a0Securities and Exchange Commission,\u00a0as updated by the Company\u2019s subsequent filings with the\u00a0Securities and Exchange Commission, and in other filings that the Company may make with the\u00a0Securities and Exchange Commission\u00a0in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.<\/p>\n

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Investor and Media Contacts:\r\nir@editasmed.com\r\nmedia@editasmed.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board\u2019s (PTAB\u2019s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR\/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad). The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC\u2019s May 2025 decision to affirm-in-part and vacate-in-part the PTAB\u2019s … <\/p>\n
Continue reading “Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-947213","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board\u2019s (PTAB\u2019s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR\/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad). The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC\u2019s May 2025 decision to affirm-in-part and vacate-in-part the PTAB\u2019s … Continue reading "Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T11:15:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\\\/Cas9 Interference\",\"datePublished\":\"2026-03-27T11:15:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/\"},\"wordCount\":789,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/\",\"name\":\"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\\\/Cas9 Interference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=\",\"datePublished\":\"2026-03-27T11:15:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\\\/Cas9 Interference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board\u2019s (PTAB\u2019s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR\/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad). The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC\u2019s May 2025 decision to affirm-in-part and vacate-in-part the PTAB\u2019s … Continue reading \"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-27T11:15:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference","datePublished":"2026-03-27T11:15:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/"},"wordCount":789,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/","name":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=","datePublished":"2026-03-27T11:15:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTU4MCM3NTA2NjYxIzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-u-s-patent-and-trademark-office-reaffirms-its-prior-decision-in-favor-of-the-broad-institute-in-crispr-cas9-interference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR\/Cas9 Interference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=947213"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947213\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=947213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=947213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=947213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}